Skip to main content
SpringerLink
Log in

Schlaglichter vom 30. Deutschen Krebskongress

Berlin, 22. bis 25. Februar 2012

Highlights from the 30th German Cancer Congress

Berlin, 22-25 February 2012

  • Aktuelle Onkologie
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Kooperationsgemeinschaft Mammographie (2012) Evaluationsbericht 2008–2009: Ergebnisse des Mammographie-Screening-Programms in Deutschland. http://www.mammo-programm.de/cms_upload/datenpool/evaluationsbericht_2008–2009_web.pdf

  2. Ranchon F et al (2011) Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs. BMC Cancer 11:478

    Article  PubMed  Google Scholar 

  3. Simons S et al (2011) Enhancing adherence to capecitabine chemotherapy by means of multidisciplinary pharmaceutical care. Support Care Cancer 19(7):1009–1018

    Article  PubMed  Google Scholar 

  4. Liekweg A et al (2012) Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer [Epub ahead of print]

  5. Bokemeyer C, Reimann J, Link KH et al (2012) Kolorektale Karzinome bei alten Patienten. Deutscher Krebskongress, 23.02. 2012, Berlin, Vortrag

  6. Twelves C, Wong A, Nowacki MP et al (2005) Capecitabine as adjuvant treatment for stage III colon cancer. NJEM 352:2696–2704

    Article  CAS  Google Scholar 

  7. Lembersky BC, Wieland HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 24:2059–2064

    Article  PubMed  CAS  Google Scholar 

  8. Andre T, Colin P, Louvet C et al (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin admistered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer. J Clin Oncol 21:2896–2903

    Article  PubMed  CAS  Google Scholar 

  9. Carrato A, Köhne C, Bedenn L et al (2006) Folinic acid modulated bolus 5-FU or infusional 5-FU or adjuvant treatment of patients of VICC stage III colon cancer. Preliminary analysis of the PETAC-2-Study. Proceed Am Soc Clin Oncol. Abstract 3563

  10. Andre T, Boni C, Mounedji-Boudiaf L et al (2009) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351

    Article  Google Scholar 

  11. Van Cutsem E, Labianca R, Bodoky G et al (2009) Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117–3125

    Article  Google Scholar 

  12. Allegra CJ, Yothers G,O’Conell MJ et al (2011) Phase III trial assessing bevacizumab in Stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29: 11–16

    Article  PubMed  CAS  Google Scholar 

  13. Goldberg R et al (2010) Adjuvant mFOLFOX6 plus or minus cetuximab in patients with KRAS mutant resected stage III colon cancer (CC): NCCTG intergroup phase III trial N0147. Proceed ASCO, abstr. 3508

  14. Cassidy J, Haller D et al (2011) Effect of dose modification on the efficacy of capecitabine: data from six randomized, phase III trials in patients with colorectal or breast cancer. Proceed ASCO, abstr. 3627

  15. Seymour MT, Thompson LC, Wasan HS et al (2011) Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377:1749–1759

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Apothekerin für klinische und onkologische Pharmazie, Sellscheid 100, 42929, Wermelskirchen, Deutschland

    A. Junker

Authors
  1. A. Junker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Junker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Junker, A. Schlaglichter vom 30. Deutschen Krebskongress. Onkologe 18, 441–444 (2012). https://doi.org/10.1007/s00761-012-2252-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-012-2252-8

Search

Navigation